Shares of Bio-Techne Corp. TECH slipped 1.78% to $59.98 Tuesday, on what proved to be an all-around favorable trading session ...

The stock's fall snapped a three-day winning streak.

Corporation announced further advancements in its ongoing strategy to bring translational discoveries to patient care by ...

Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet ...

Equities research analysts at Evercore ISI assumed coverage on shares of Bio-Techne (NASDAQ:TECH – Get Free Report) in a ...

Fintel reports that on March 18, 2025, Evercore ISI Group initiated coverage of Bio-Techne (NasdaqGS:TECH) with a Outperform ...

MINNEAPOLIS, March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, ...

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight ...

Evercore ISI initiated coverage of Bio-Techne (TECH) with an Outperform rating and $75 price target The firm believes that current volatility ...

Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed ...